FAM111B and central nervous system cancer: Time-dependent ROC analysis demonstrated that the area under the curve (AUC) values for predicting the 1-year, 3-year, and 5-year survival rates of glioma patients were 0.760, 0.811, and 0.776, respectively (Fig. 2R), highlighting FAM111B’s utility as a reliable biomarker for glioma diagnosis.